Evidence map›Paper›PMID 42664364›Full record

Trial reportPloS one2026

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

Nobuo Nagano, Shin Tokunaga, Shinji Asada, Masafumi Fukagawa, Tadao Akizawa

3 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04766385 phase3completednot on this map

A Phase 3, Open-label, Single-arm Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

TypeinterventionalSponsorKyowa Kirin Co., Ltd.Ran2021 to 2021Enrolled54ConditionsHyperphosphatemiaArmsKHK7791
NCT04766398 phase3completednot on this map

A Phase 3, Randomized, Double-blind, Placebo-controlled, Phosphate Binder-combination, Parallel-group Comparative Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

TypeinterventionalSponsorKyowa Kirin Co., Ltd.Ran2021 to 2021Enrolled169ConditionsHyperphosphatemiaArmsKHK7791, Placebo
NCT04767581 phase3completednot on this map

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Comparative Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

TypeinterventionalSponsorKyowa Kirin Co., Ltd.Ran2021 to 2021Enrolled165ConditionsHyperphosphatemiaArmsKHK7791, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nobuo NaganoKidney Disease and Dialysis Center, Hidaka Hospital, Hidaka-kai, Gunma, Japan.ORCID https://orcid.org/0000-0001-6527-3286
Shin TokunagaMedical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Shinji AsadaMedical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0000-0002-7717-8945
Masafumi FukagawaDivision of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Tadao AkizawaDivision of Nephrology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registrationThe original clinical trials were registered at ClinicalTrials.gov under the identifiers NCT04767581, NCT04766398, and NCT04766385.

Indexed as

HyperphosphatemiaRenal DialysisSulfonamidesHumansSulfonamides

Identifiers

PMID42664364
PMCPMC13524331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.